Advert - Angelini Pharma UK-I Limited - Case AUTH/3916/5/24

Angelini was ruled in breach of Clause 2 of the 2021 Code in relation to an in-person presentation by a contracted speaker at a company-organised promotional meeting, and its recording, which criticised the European Medicines Agency’s licensing decisions.

For that, reference to the European Medicines Agency, inadequate briefing of the speaker and lack of action to correct the speaker, and for promotion at two meetings that was inconsistent with the marketing authorisation for cenobamate, and for failing to certify the on-demand versions of two videos and 14 sets of slides (13 of which also lacked prescribing information and the adverse event reporting statement) and two on-street banners, Angelini was ruled in breach of the following clauses of the 2021 Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry

Clause 5.1 - Failing to maintain high standards

Clause 8.1 - Failing to certify promotional material

Clause 11.2 - Promoting a medicine for an unlicensed indication

Clause 12.1 - Failing to include prescribing information

Clause 12.9 - Failing to include the adverse event reporting statement

Clause 15.2 - Including a reference to the licensing authority when this was not specifically required by the licensing authority

Advert 24 November 2025